Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficac — Paul S. Aisen (COGNITION TH
Cognition Therapeutics, Inc. (CogRx) is developing CT1812, a disease-modifying drug for Alzheimer’s disease. CT1812 is the first highly brain penetrant selective sigma-2 receptor antagonist small mole
| Project title | Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficac |
|---|---|
| Project number | 5R01AG065248-03 |
| PI name | Paul S. Aisen |
| Institution | COGNITION THERAPEUTICS, INC. |
| Funding mechanism | R01 |
| Agency | NIA |
| Award amount | $13.13M |
| Fiscal year | 2024 |
| Project start | 2020-06-01T00:00:00 |
| Project end | 2027-05-31T00:00:00 |
| Abstract | Cognition Therapeutics, Inc. (CogRx) is developing CT1812, a disease-modifying drug for Alzheimer’s disease. CT1812 is the first highly brain penetrant selective sigma-2 receptor antagonist small mole |
| Key terms | <AD dementia><Abeta clearance><Adverse Experience><Adverse event><Affect><Alzheimer Type Dementia><A |
$799/mo
Try GrantRadar →